Healthcare products company West Pharmaceutical Services (NYSE: WST) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 13.8% year on year to $872.3 million. Guidance for next quarter’s revenue was better than expected at $827.5 million at the midpoint, 0.8% above analysts’ estimates. Its non-GAAP profit of $2.37 per share was 13.9% above analysts’ consensus estimates.
Is now the time to buy West Pharmaceutical Services? Find out by accessing our full research report, it’s free.
West Pharmaceutical Services (WST) Q2 CY2026 Highlights:
- Revenue: $872.3 million vs analyst estimates of $842.7 million (13.8% year-on-year growth, 3.5% beat)
- Adjusted EPS: $2.37 vs analyst estimates of $2.08 (13.9% beat)
- The company lifted its revenue guidance for the full year to $3.36 billion at the midpoint from $3.32 billion, a 1.2% increase
- Management raised its full-year Adjusted EPS guidance to $8.95 at the midpoint, a 4.4% increase
- Operating Margin: 20.5%, in line with the same quarter last year
- Free Cash Flow Margin: 9.3%, down from 13.3% in the same quarter last year
- Market Capitalization: $25.32 billion
Company Overview
Founded in 1923 and serving as a critical link in the pharmaceutical supply chain, West Pharmaceutical Services (NYSE: WST) manufactures specialized packaging, containment systems, and delivery devices for injectable drugs and healthcare products.
Revenue Growth
Reviewing a company’s long-term sales performance reveals insights into its quality. Any business can put up a good quarter or two, but the best consistently grow over the long haul. Regrettably, West Pharmaceutical Services’s sales grew at a mediocre 5.7% compounded annual growth rate over the last five years. This was below our standard for the healthcare sector and is a rough starting point for our analysis.
We at StockStory place the most emphasis on long-term growth, but within healthcare, a half-decade historical view may miss recent innovations or disruptive industry trends. West Pharmaceutical Services’s annualized revenue growth of 7.5% over the last two years is above its five-year trend, suggesting some bright spots. 
This quarter, West Pharmaceutical Services reported year-on-year revenue growth of 13.8%, and its $872.3 million of revenue exceeded Wall Street’s estimates by 3.5%. Company management is currently guiding for a 2.8% year-on-year increase in sales next quarter.
Looking further ahead, sell-side analysts expect revenue to grow 1.3% over the next 12 months, a deceleration versus the last two years. This projection doesn’t excite us and indicates its products and services will see some demand headwinds.
ALSO WORTH WATCHING: Nvidia’s Quiet Partner. Nvidia’s chips cost a hundred grand. The connectors that make them work cost even more. One company makes them all.
Every AI server needs specialized infrastructure the chip companies don’t make. High-speed cables. Power connectors. Thermal sensors. This 90-year-old company built a monopoly on it. The AI boom just started. This stock is still flying under the radar. Claim The Stock Ticker Here for FREE.
Adjusted Operating Margin
Adjusted operating margin is a key measure of profitability. Think of it as net income (the bottom line) excluding the impact of non-recurring expenses, taxes, and interest on debt - metrics less connected to business fundamentals.
West Pharmaceutical Services has been an efficient company over the last five years. It was one of the more profitable businesses in the healthcare sector, boasting an average adjusted operating margin of 22.7%.
Analyzing the trend in its profitability, West Pharmaceutical Services’s adjusted operating margin decreased by 5.5 percentage points over the last five years. This raises questions about the company’s expense base because its revenue growth should have given it leverage on its fixed costs, resulting in better economies of scale and profitability.
This quarter, West Pharmaceutical Services generated an adjusted operating margin profit margin of 21.8%, up 1.5 percentage points year on year. This increase was a welcome development and shows it was more efficient.
Earnings Per Share
We track the long-term change in earnings per share (EPS) for the same reason as long-term revenue growth. Compared to revenue, however, EPS highlights whether a company’s growth is profitable.
West Pharmaceutical Services’s unimpressive 4% annual EPS growth over the last five years aligns with its revenue performance. This tells us it maintained its per-share profitability as it expanded.
In Q2, West Pharmaceutical Services reported adjusted EPS of $2.37, up from $1.84 in the same quarter last year. This print easily cleared analysts’ estimates, and shareholders should be content with the results. Over the next 12 months, Wall Street expects West Pharmaceutical Services’s full-year EPS to grow 5% from $8.50 to $8.92.
Key Takeaways from West Pharmaceutical Services’s Q2 Results
We enjoyed seeing West Pharmaceutical Services beat analysts’ full-year EPS guidance expectations this quarter. We were also glad its revenue outperformed Wall Street’s estimates. Zooming out, we think this was a solid print. The stock traded up 7.3% to $384.97 immediately after reporting.
Sure, West Pharmaceutical Services had a solid quarter, but if we look at the bigger picture, is this stock a buy? What happened in the latest quarter matters, but not as much as longer-term business quality and valuation, when deciding whether to invest in this stock. We cover that in our actionable full research report which you can read here (it’s free).
